PRAX (Praxis Precision Medicines) Altman Z2-Score: 28.57 (As of Jun. 28, 2026) — 1571% Above Median


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $327.79
GF Value $31.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Praxis Precision Medicines Altman Z2-Score?

Praxis Precision Medicines PRAX -0.02% 38 Altman Z2-Score is 28.57 as of Jun. 28, 2026, which is 1571% above its 10-year median of 1.71. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $31.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, Praxis Precision Medicines ranks better than 95.85% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Praxis Precision Medicines has a Altman Z2-Score of 28.57, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Praxis Precision Medicines's Altman Z2-Score or its related term are showing as below:

PRAX' s Altman Z2-Score Range Over the Past 10 Years
Min: -25.01   Med: 1.71   Max: 28.57
Current: 28.57

During the past 8 years, Praxis Precision Medicines's highest Altman Z2-Score was 28.57. The lowest was -25.01. And the median was 1.71.


Praxis Precision Medicines  (NAS:PRAX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Praxis Precision Medicines Altman Z2-Score Related Terms


Praxis Precision Medicines Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Praxis Precision Medicines's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Praxis Precision Medicines Altman Z2-Score Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 4.50 -21.11 -24.50 9.21 13.15

Praxis Precision Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.54 1.71 -2.80 13.15 28.57

PRAX vs KRYS, CYTK, NUVL: Altman Z2-Score Comparison

For the Biotechnology subindustry, Praxis Precision Medicines's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Praxis Precision Medicines Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Altman Z2-Score falls into.


PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Praxis Precision Medicines Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Praxis Precision Medicines's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5119+3.26*-0.8441+6.72*-0.2236+1.05*28.064
=28.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $1,460.20 Mil.
Total Current Assets was $797.77 Mil.
Total Current Liabilities was $50.24 Mil.
Retained Earnings was $-1,232.57 Mil.
Pre-Tax Income was -92.561 + -88.911 + -73.934 + -71.127 = $-326.53 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $50.24 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(797.774 - 50.241)/1460.202
=0.5119

X2=Retained Earnings/Total Assets
=-1232.569/1460.202
=-0.8441

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-326.533 - 0)/1460.202
=-0.2236

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1409.961 - 0)/50.241
=28.064

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Praxis Precision Medicines has a Altman Z2-Score of 28.57 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 28.57 mean?
Praxis Precision Medicines (PRAX) has a Altman Z2-Score of 28.57 as of Jun. 28, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Praxis Precision Medicines and its competitors. This is 1571% above median its historical median of 1.71. According to the industry distribution chart, Praxis Precision Medicines ranks #58 out of 1396 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Praxis Precision Medicines' Altman Z2-Score too high?
Praxis Precision Medicines' current Altman Z2-Score of 28.57 is 1571% above median its 10-year median of 1.71. Based on the distribution chart, Praxis Precision Medicines ranks #58 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Altman Z2-Score compare to KRYS and CYTK?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #58 out of 1396 companies for Altman Z2-Score. This places Praxis Precision Medicines in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current Altman Z2-Score is 28.57, which is 1571% above median its own 10-year median of 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.07, compared to a current price of $327.79 — trading 955% above its estimated fair value. The current Altman Z2-Score is 28.57, which is 1571% above median its 10-year median of 1.71. Praxis Precision Medicines' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Altman Z2-Score is 28.57 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $327.79 is trading 955% above its estimated GF Value™ of $31.07. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Altman Z2-Score: 28.57 (1571% above median its 10-year median of 1.71)
  • GF Value™: $31.07 vs. price of $327.79 (955% above fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$327.79
Price
$31.07
GF Value